GammaCan International, Inc. Discovers Anti-Angiogenic Properties in Plasma-Derived IgG; Company Files Patent Application Pertaining to Disorders of Neovascularization Including Cancer and Other Diseases

Published: Jun 28, 2007

KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, announced today that its Chief Scientist, Professor Yehuda Shoenfeld, M.D., FRCP, has discovered that gamma-immunoglobulins, or IgG, manufactured from human plasma, contain sub-fractions with potent anti-angiogenic properties which may have application in disorders of neovascularization, including cancer and other diseases. This discovery is the subject of a recent patent application filing with the U.S. Patent and Trademark Office.

Back to news